Last year, Tandem Diabetes Care Inc generated 706.94M USD for its biggest-performing segment, Pump. The Domestic made the largest contribution, accounting for 353.88M USD last year. For the latest quarter, Tandem Diabetes Care Inc reported the revenue of 114.65M USD for the period ending 2026-06-30, which came from the top-performing segment, Pump. Domestic contributed the highest revenue, at 83.00M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Pump

Supplies and other - Domestic

Supplies and other-International

Deferral for Tandem Choice program-Domestic

Infusion sets

Cartridges

Other

Adjustment for Tandem Choice program

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Pump

706.94M(69.67%)

434.17M(46.18%)

374.29M(49.50%)

431.91M(53.91%)

416.36M(59.24%)

314.71M(63.09%)

247.59M(68.34%)

Supplies and other - Domestic

197.54M(19.47%)

161.97M(17.23%)

116.54M(15.41%)

--(--)

Supplies and other-International

110.26M(10.87%)

313.81M(33.38%)

290.44M(38.41%)

--(--)

Deferral for Tandem Choice program-Domestic

--(--)

30.25M(3.22%)

-25.11M(-3.32%)

--(--)

Infusion sets

--(--)

258.49M(32.26%)

197.45M(28.09%)

127.76M(25.61%)

77.25M(21.32%)

Cartridges

--(--)

112.16M(14.00%)

86.88M(12.36%)

55.23M(11.07%)

36.68M(10.12%)

Other

--(--)

2.21M(0.28%)

2.11M(0.30%)

1.14M(0.23%)

786.00K(0.22%)

Adjustment for Tandem Choice program

--(--)

-3.55M(-0.44%)

--(--)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

Domestic

International

Adjustment for Tandem Choice program

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Domestic

353.88M(50.06%)

328.63M(75.69%)

289.55M(77.36%)

592.31M(73.60%)

524.91M(74.69%)

415.68M(83.33%)

302.08M(83.38%)

International

353.06M(49.94%)

105.54M(24.31%)

84.75M(22.64%)

212.45M(26.40%)

177.89M(25.31%)

83.15M(16.67%)

60.22M(16.62%)

Adjustment for Tandem Choice program

--(--)